• Sonuç bulunamadı

Lamivudine resistance in untreated chronic hepatitis b patients in Turkey

N/A
N/A
Protected

Academic year: 2021

Share "Lamivudine resistance in untreated chronic hepatitis b patients in Turkey"

Copied!
5
0
0

Yükleniyor.... (view fulltext now)

Tam metin

Şekil

Table 1. The mutations, HBeAg/anti-HBe status and viral loads of the patients with mutations
Table 2. Power Analysis: Group sample sizes of 61 and 6 achieve 99% power to detect a difference of 190.754.925 between the YMDD motif group (mean±SD of 86.882.913±117.564) and YMDD mutation group (mean±SD of 277.637.838±192.906.935) with a significance le

Referanslar

Benzer Belgeler

In the present study, no statistically significant difference was deter- mined in the age, gender, ECOG status, Ann Arbor stage, presence of B symptoms, serum ALT, serum TB, and

To the best of our knowledge, there is no study assessing fine motor coordination and hand functions in patients with chronic hepatitis B (CHB) without the findings of LC; thus,

In this study that focused on comparing Qiagen and Iontek HBV-DNA quantitation kits, HBV-DNA loads were defined in IU/mL, but these results were converted to log values for

No significant difference was found between the cases with positive and negative ANA and ASMA outcomes in the patient group in terms of age, BMI, USG, total cholesterol

Although there are several studies on anti-HDV seroprevalence rates in hepatitis B surface antigen (HBsAg)-positive patients in Turkey, studies on HDV-RNA prevalence in this

Monitoring of hepatitis B virus surface antigen escape mutations and concomitantly nucleos(t)ide analog resistance mutations in Turkish patients with chronic hepatitis B. Coppola

This is important as chronic viral hepatitis progresses more rapidly to end-stage liver disease in human immunodeficiency virus-infected patients.. Once diagnosed, there are

Objective: Several studies have demonstrated that psychiatric patients are at increased risk for hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency